Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 9Recruiting 3Unknown 2Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 47Rectal Neoplasms 29Stomach Neoplasms 24Colorectal Neoplasms 24Triple Negative Breast Neoplasms 18Neoplasm Metastasis 10Colonic Neoplasms 10Nasopharyngeal Carcinoma 9Locally Advanced Rectal Cancer 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Pancreatic Neoplasms 5Brain Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroendocrine Tumors 3HER2-positive Breast Cancer 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Advanced Solid Tumors 3Recurrence 2Neoplasm, Residual 2Meningeal Neoplasms 2Locally Advanced Colorectal Cancer 2Esophageal Squamous Cell Carcinoma 2Early Low Rectal Cancer 2Colorectal Cancer Metastatic 2

Interventions

Oxaliplatin 6Fluorouracil 5Leucovorin 4Blood Specimen Collection 4Pafolacianine 3Cisplatin 3Cetuximab 3Capecitabine 3Bevacizumab 3pembrolizumab 2atezolizumab 2XELOX 2Surveys and Questionnaires 2Standard of Care 2Paclitaxel 2Irinotecan 2IDRX-42 2Gemcitabine 2Folfox protocol 2Endoscopic Mucosal Resection 2Drug Therapy 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1sodium thiosulfate 1sodium propionate 1sacituzumab govitecan 1s-formylglutathione hydrolase 1repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Gastrointestinal Neoplasms × Capecitabine × Clear all
NCT07056777 2026-01-13

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Zhejiang Doer Biologics Co., Ltd.

Phase 1/2 Recruiting
186 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Henry Ford Health System

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡